CU6 2.29% $7.15 clarity pharmaceuticals ltd

CU6 - Media and Industry News, page-447

  1. 266 Posts.
    lightbulb Created with Sketch. 187
    Does Chris acknowledge competition?
    He has done it in a more graceful manner before (which to me, makes the comment to the UBS analysts strange, and even the bit that has been shared on HC is even stranger).

    Here is a summary of what he says on a recent interview (shared below - March 2024);
    1) He acknowledges competitors, and states that the competitors are all at different stages (Lantheus - (established) and Blue Earth - (new)). He comments specifically on the difficulty that new entrants like Clarity would have in taking market share! This, while also stating that Telix is itself entering and seeking to take market share in other indications!
    2) He specifically says "I think they (Clarity) are doing nice work ...", and also states the steps that Clarity need to take to get there: "They have to demonstrate that they can scale and commercially deliver to be commercially viable - that's their next big step ahead!"
    3) He mentions that they (Telix) "just acquired one of Clarity's significant supply chains": why would that matter, and why mention it, if Clarity is a non entity? A question for me on this one is: Is he indicating a willingness to slow down the competition, or was this unrelated?

    On the interviewer's comment that says, "Healthy competition is good", he says, "No-one wants to swim where there is no water flowing!" All good so far, I think!

    In conclusion: YES, they are worried. They are right to be.


 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
(20min delay)
Last
$7.15
Change
0.160(2.29%)
Mkt cap ! $2.289B
Open High Low Value Volume
$7.05 $7.19 $6.91 $3.595M 509.0K

Buyers (Bids)

No. Vol. Price($)
1 10000 $7.12
 

Sellers (Offers)

Price($) Vol. No.
$7.16 3007 3
View Market Depth
Last trade - 16.10pm 05/11/2024 (20 minute delay) ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.